Novo Nordisk said on Thursday it expects Wegovy to be approved for sale in China this year and plans to soon launch the popular weight-loss drug in the largest Asian market with capped volumes. The upcoming launch in China will initially focus on patients paying out-of-pocket for Wegovy, the head of Novo's business in China, Christine Zhou Xiaping, told an investor meeting at the company's headquarters outside Copenhagen.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles